Invitrogen Corp., a provider of products and services that support academic and government research institutions and pharmaceutical companies, has acquired Sentigen Holding Corp. for $26 million. The New Jersey-based Sentigen has subsidiaries in biosciences and molecular technology....
Has Mark Green found a way to defuse the stem cell issue? The Republican gubernatorial candidate has called for $25 million in state funding to develop stem cell research techniques that do not involve the destruction of embryos, a proposal the Doyle campaign calls irresponsible...
Beth Donley, the new executive director of WiCell, UW-Madison's non-profit organization that controls all 21 federally funded stem cell lines, has plans to bring WiCell - and stem cell research - to another level. In her previous capacity, she led litigation and patent-drafting efforts for...
A group of researchers at the University of Wisconsin-Madison has discovered a way to "pirate" nature's sugars and create a biological effect that produces more of the cancer- and infection-fighting agents used in pharmaceuticals. Their findings were published in the Sept. 1 edition of the...
A Wisconsin biotechnology company is seeking to commercialize medicines to treat the diseases of aging, and it has adopted a business model that seeks to shoot down one degenerative disease at a time - perhaps before stem cell research gets a chance to. ...
Mithridion, Inc., a Madison-based biopharmaceutical start-up, is moving into the next phase of drug research and development with $296,800 in federal grants. One grant, which is designed to promote technology transfer, will enable collaboration between the company and University of Wisconsin-Madison researcher Jeffrey Johnson....
Yet another discovery has roiled the ongoing debate over the use of human embryonic stem cells in scientific research. This time, researchers believe they have eliminated the main objections to stem cell research - the destruction of embryos. ...
Scientific Protein Laboratories, a manufacturer of active pharmaceutical ingredients, has been purchased by a publicly traded buyout firm with $8.4 billion in capital resources. The acquisition will allow SPL to expand production....
A recent Wisconsin Biotechnology and Medical Device Association breakfast raised the question of research park expansion to accommodate more life-science businesses. But the director of Milwaukee County Research Park says the demand is just not there. ...
Covance, the drug development firm with facilities in Madison, would like to build a drug testing research facility in Chandler, Ariz., but it must contend with more than the usual zoning and traffic issues. Standing in its way is a determined protest from the People...